1e
19
1
49
2
2
18
1b
1d
18
34
63
1d
2 29
1d
25
Daniel J Landsburg, MD
78
63
Associate Professor of Clinical Medicine (Hematology-Oncology)
28
86
3
5f
Medical Director, Infusion Services, Hospital of the University of Pennsylvania
c2
Faculty Leader, Hematology/Oncology Fellowship Quality Improvement and Patient Safety Education, Hospital of the University of Pennsylvania
ba
Faculty mentor, Department of Medicine Healthcare Leadership in Quality Residency Track, Hospital of the University of Pennsylvania
99
Physician Leader, Oncology Clinical Effectiveness Team, Hospital of the University of Pennsylvania
11
Department: Medicine
4
1
b
1d
46
Contact information
4d
4
3
3
3
2
4
b
1f
4d
Division of Hematology Oncology
2d Perelman Center for Advanced Medicine
22 12th Floor, South Pavilion
16 Office #12-182
3e 3400 Civic Center Boulevard
Philadelphia, PA 19104
26
2d Perelman Center for Advanced Medicine
22 12th Floor, South Pavilion
16 Office #12-182
3e 3400 Civic Center Boulevard
Philadelphia, PA 19104
2e
Office: 215-615-7361
32 Fax: 215-615-5888
24
f
32 Fax: 215-615-5888
24
13
Education:
21 7 BA c
33 University of Pennsylvania, 2004.
21 7 MD c
3d Temple University School of Medicine, 2008.
c
3
3
3
3
8b
Permanent link21 7 BA c
33 University of Pennsylvania, 2004.
21 7 MD c
3d Temple University School of Medicine, 2008.
c
2 29
21
1e
1d
24
5e
18 Hodgkin lymphoma
2c Autologous stem cell transplantation
16 CART-19 therapy
62
1b Quality improvement
15 Patient safety
65
39 Molecular classification of large B cell lymphoma
16 CART-19 therapy
e 29
27
Description of Clinical Expertise
20 B cell lymphoma18 Hodgkin lymphoma
2c Autologous stem cell transplantation
16 CART-19 therapy
62
Description of Other Expertise
24 Clinical operations1b Quality improvement
15 Patient safety
65
Description of Research Expertise
32 Therapy for large B cell lymphoma39 Molecular classification of large B cell lymphoma
16 CART-19 therapy
e 29
23
179 Landsburg DJ, Musoke N, Gentile C, Brooks TR, Nasta SD, Barta SK, Carter JS, Chong EA, Svoboda J, Schuster SJ, Thomas CJ, Tomasulo EB, Cook MR, Morrissette JJD, Caimi PF, Hill BT.: Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma. Leukemia 40(3): 694-697, Feb 2026.
1b8 Landsburg DJ, Frigault MJ, Heim M, Foley SR, Hill B, Schofield G, Jacobson CA, Jaglowski S, Locke FL, Ram R, Riedell PA, Shah G, Popplewell LL, Tiwari R, Lim S, Majdan M, Masood A, Pasquini M, Turtle CJ.: Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry. J Immunother Cancer 13(2): e009890, Feb 2025.
1be Schneider M, Nasta SD, Barta SK, Chong EA, Svoboda J, Schuster SJ, Landsburg DJ.: Analysis of Histologic, Immunohistochemical and Genomic Features of Large B Cell Lymphoma Tumors May Predict Response to Polatuzumab Vedotin Based Therapy in Patients With Relapsed/Refractory Disease. Clin Lymphoma Myeloma Leuk 25(1): 45-51, Jan 2025 Notes: DOI: 10.1016/j.clml.2024.08.010
1f2 Maillie L, Nasta SD, Svoboda J, Barta SK, Chong EA, Garfall AL, Gill SI, Porter DL, Schuster SJ, Catania C, Frey NV, Landsburg DJ.: Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B-cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell Therapy. Transplant Cell Ther 00912-1.(25): S2666-6367, Jan 2025 Notes: DOI: 10.1016/j.jtct.2025.01.884
12c Landsburg, DJ: Improving Cure Rates for Patients with Newly Diagnosed Large B-Cell Lymphomas: Targeted Therapies for High-Risk Pathologic Subgroups as Defined by Clinical Laboratory Testing. Cancers (Basel) 17(1): 18, Dec 2024.
153 Landsburg DJ, Morrissette JJD, Nasta SD, Barta SK, Schuster SJ, Chong EA, Svoboda J, Barlev A, Bagg A, Priore SF.: Genomic features of newly diagnosed large B cell lymphoma with or without subsequent disease progression. Cancer Res Commun 4(11): 2947-2954, Oct 2024.
16b Ni V, Nasta SD, Barta SK, Schuster SJ, Chong EA, Svoboda J, Morrissette JJD, Barlev A, Bagg A, Priore SF, Landsburg DJ.: Identification of a clinicopathologic prognostic index for newly diagnosed large B cell lymphoma patients treated with R-CHOP. Haematologica 110(4): 1023-1027, Nov 2024.
12c Schneider, Michael, Landsburg, Daniel: The role of pathologic testing in the diagnosis and management of patients with diffuse large B cell lymphoma: a narrative review. Annals of Lymphoma 8: doi: 10.21037/aol-23-19, Mar 2024.
1f8 Landsburg DJ, Nasta SD, Svoboda J, Gerson JN, Schuster SJ, Barta SK, Chong EA, Difilippo H, Weber E, Cunningham K, Catania C, Garfall AL, Stadtmauer EA, Frey NV, Porter DL.: Survival outcomes for patients with relapsed/refractory aggressive B cell lymphomas following receipt of high dose chemotherapy/autologous stem transplantation and/or chimeric antigen receptor-modified T cells. Transplant Cell Ther 29(8): 495-503. Aug 2023.
145 Landsburg DJ, Morrissette JJ, Nasta SD, Barta SK, Schuster SJ, Svoboda J, Chong EA, Bagg A.: TP53 mutations predict for poor outcomes in patients with newly-diagnosed aggressive B cell lymphomas in the current era. Blood Adv 7(23): 7243-7253, Oct 2023.
2c
7
1d
1f
Selected Publications
324 Michael Schneider, Luca Paruzzo, Federico Stella, Julia Han Noll, Matthew Ho, Victor Babatunde, Bianca Ho, Pooja Devi, Elise A. Chong, Stefan K. Barta, Sunita D. Nasta, Jakub Svoboda, Jordan Carter, Michael R. Cook, Nasheed M. Hossain, Colin J. Thomas, Vrutti Patel, Vitor B. de Souza, Mohannad H. Alkhatib, Ziyu Li, Melody Tan, Peter Michener, Puneeth Guruprasad, Antonio Imparato, Alberto Carturan Patrizia Porazzi, Joseph A. Fraietta, Stephen J. Schuster, Ivan 9 Maillard, Marco Ruella and Daniel J. Landsburg: Naïve CD4+ T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy. Nature Communications, In Press March 2026.179 Landsburg DJ, Musoke N, Gentile C, Brooks TR, Nasta SD, Barta SK, Carter JS, Chong EA, Svoboda J, Schuster SJ, Thomas CJ, Tomasulo EB, Cook MR, Morrissette JJD, Caimi PF, Hill BT.: Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma. Leukemia 40(3): 694-697, Feb 2026.
1b8 Landsburg DJ, Frigault MJ, Heim M, Foley SR, Hill B, Schofield G, Jacobson CA, Jaglowski S, Locke FL, Ram R, Riedell PA, Shah G, Popplewell LL, Tiwari R, Lim S, Majdan M, Masood A, Pasquini M, Turtle CJ.: Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry. J Immunother Cancer 13(2): e009890, Feb 2025.
1be Schneider M, Nasta SD, Barta SK, Chong EA, Svoboda J, Schuster SJ, Landsburg DJ.: Analysis of Histologic, Immunohistochemical and Genomic Features of Large B Cell Lymphoma Tumors May Predict Response to Polatuzumab Vedotin Based Therapy in Patients With Relapsed/Refractory Disease. Clin Lymphoma Myeloma Leuk 25(1): 45-51, Jan 2025 Notes: DOI: 10.1016/j.clml.2024.08.010
1f2 Maillie L, Nasta SD, Svoboda J, Barta SK, Chong EA, Garfall AL, Gill SI, Porter DL, Schuster SJ, Catania C, Frey NV, Landsburg DJ.: Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B-cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell Therapy. Transplant Cell Ther 00912-1.(25): S2666-6367, Jan 2025 Notes: DOI: 10.1016/j.jtct.2025.01.884
12c Landsburg, DJ: Improving Cure Rates for Patients with Newly Diagnosed Large B-Cell Lymphomas: Targeted Therapies for High-Risk Pathologic Subgroups as Defined by Clinical Laboratory Testing. Cancers (Basel) 17(1): 18, Dec 2024.
153 Landsburg DJ, Morrissette JJD, Nasta SD, Barta SK, Schuster SJ, Chong EA, Svoboda J, Barlev A, Bagg A, Priore SF.: Genomic features of newly diagnosed large B cell lymphoma with or without subsequent disease progression. Cancer Res Commun 4(11): 2947-2954, Oct 2024.
16b Ni V, Nasta SD, Barta SK, Schuster SJ, Chong EA, Svoboda J, Morrissette JJD, Barlev A, Bagg A, Priore SF, Landsburg DJ.: Identification of a clinicopathologic prognostic index for newly diagnosed large B cell lymphoma patients treated with R-CHOP. Haematologica 110(4): 1023-1027, Nov 2024.
12c Schneider, Michael, Landsburg, Daniel: The role of pathologic testing in the diagnosis and management of patients with diffuse large B cell lymphoma: a narrative review. Annals of Lymphoma 8: doi: 10.21037/aol-23-19, Mar 2024.
1f8 Landsburg DJ, Nasta SD, Svoboda J, Gerson JN, Schuster SJ, Barta SK, Chong EA, Difilippo H, Weber E, Cunningham K, Catania C, Garfall AL, Stadtmauer EA, Frey NV, Porter DL.: Survival outcomes for patients with relapsed/refractory aggressive B cell lymphomas following receipt of high dose chemotherapy/autologous stem transplantation and/or chimeric antigen receptor-modified T cells. Transplant Cell Ther 29(8): 495-503. Aug 2023.
145 Landsburg DJ, Morrissette JJ, Nasta SD, Barta SK, Schuster SJ, Svoboda J, Chong EA, Bagg A.: TP53 mutations predict for poor outcomes in patients with newly-diagnosed aggressive B cell lymphomas in the current era. Blood Adv 7(23): 7243-7253, Oct 2023.
2c